Physician profile
Paul Bates
NPI 1245481365
$1,407.97
in general payments reported to CMS, 2019-2025
12 companies · $36.32 in 2025
The $36.32 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $216 · 2023: $608 · 2024: $162 · 2025: $36.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.44 | 2021-2024 | Lifevest |
| Ipsen Biopharmaceuticals, INC | $165.80 | 2023-2025 | Dysport |
| Silk Road Medical, INC. | $146.05 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Neurocrine Biosciences, INC. | $127.00 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Boston Scientific Corporation | $119.27 | 2024 | Watchman Access System |
| Intuitive Surgical, INC. | $96.57 | 2023 | Da Vinci Surgical System |
| Amgen INC. | $93.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $85.01 | 2021 | |
| Merz Pharmaceuticals, LLC | $42.85 | 2023-2024 | Xeomin, Inbrija |
| Abbvie INC. | $19.90 | 2025 | |
| Bioventus LLC | $18.33 | 2023 | L300 Go System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.